Stage 2 · Toolkit 2.7
Immunotoxicity & Biologics Nonclinical Safety
Support immune-active products, biologics, monoclonal antibodies, and immunomodulators.
What it helps control
Operational support
Helps teams establish the procedures, working records, trackers, and evidence needed for Immunotoxicity & Biologics Nonclinical Safety.
How it helps your team
Surface evidence gaps and dependencies before they delay IND, CTA, or first-in-human decisions.
Designed for
Nonclinical development, toxicology, safety pharmacology, bioanalysis, Regulatory Affairs, and Quality teams.
Included files
Know exactly what the toolkit contains
The file names below show what is included. File contents become available only after purchase.
Word documents
- Immunotoxicity Assessment Plan
- Biologics Nonclinical Safety Strategy
- Immunogenicity Risk Assessment
- Cytokine Release Risk Assessment
- Species Relevance Justification Template
- Immunotoxicity Key Finding Summary
Excel workbooks
- Immunotoxicity Evidence Tracker
- Species Relevance Matrix
- Immunogenicity Risk Tracker
- Cytokine Release Risk Tracker
- Source Data Reference Log
Related toolkits
Continue within stage 2
Nonclinical Development Plan & IND/CTA-Enabling Strategy
Define the nonclinical package needed to support IND, CTA, first-in-human, and clinical development.
2.2GLP Compliance & Sponsor Oversight
Ensure GLP studies are appropriately planned, overseen, monitored, documented, reported, and archived.
2.3Toxicology Study Planning & Management
Manage toxicology studies and interpret key findings for regulatory and FIH readiness.